New obesity drug combo enters early human testing
NCT ID NCT06916065
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage study tested two drugs, eloralintide and tirzepatide, in 188 adults with overweight or obesity. The goal was to check safety, side effects, and how the drugs move through the body. Participants received weekly injections under the skin for up to 26 weeks. Results will help decide if larger studies are worth pursuing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Eloralintide and tirzepatide
What this could lead to
If this early study shows the drugs are safe and well-tolerated, it could pave the way for larger trials testing a new combination treatment for weight loss.
What could go wrong
This is a very early Phase 1 trial focused on safety and how the body processes the drugs, not on weight loss itself. The combination may cause side effects or not work better than existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.